Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT01074931
First received: February 22, 2010
Last updated: July 7, 2011
Last verified: July 2011

February 22, 2010
July 7, 2011
April 2008
May 2010   (final data collection date for primary outcome measure)
  • Evolution of the HIV Viral Response [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: No ]
    The protocol recommended that HIV viral load tests be performed at baseline and each study visit. Test results indicate the number of HIV-1 ribonucleic acid (RNA) copies per milliliter (mL). The number of participants who underwent testing and had detectable levels (greater than 50 copies/mL) or undetectable levels (less than 50 copies/mL) are presented by subgroup. Study visits were to occur at approximately 3, 6, 12, and 18 months after starting treatment. The exact dates of each visit depended on the physician's judgment, so data are reported for Visits 1 through 4 rather than by month.
  • Evolution of CD4 Count [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: No ]
    The evolution of participants' CD4-positive (CD4+) T-lymphocyte counts after starting the lopinavir/ritonavir-containing regimen was to be assessed by measuring the number of CD4+ cells at baseline and each subsequent study visit. CD4+ count results are reported as the number of CD4+ cells per cubic millimeter (cmm). Study visits were to occur at approximately 3, 6, 12, and 18 months after starting treatment. The exact dates of each visit depended on the physician's judgment, so data are reported for Visits 1 through 4 rather than by month.
  • Evolution of the Tolerance Issues [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: Yes ]
    At each study visit, treating physicians evaluated participants and used their clinical judgment to determine if they were tolerating the lopinavir/ritonavir-containing regimen. Study visits were to occur at approximately 3, 6, 12, and 18 months after starting treatment. The exact dates of each visit depended on the physician's judgment, so data are reported for Visits 1 through 4 rather than by month.
  • Evolution of the HIV viral response [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: No ]
  • Evolution of CD4 count [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: No ]
  • Evolution of the tolerance issues [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01074931 on ClinicalTrials.gov Archive Site
  • Number of Participants Who Missed Doses, Interrupt or Discontinue Regimen, and Experience Changes in Dosage or of Combination Regimen [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: Yes ]
    Visits were to occur at approximately 3, 6, 12, and 18 months after starting treatment. The frequency with which each participant forgot to take their medication since the last visit and discontinuations of treatment and the reasons were documented at each visit and are summarized. The number of participants changing from lopinavir/ritonavir soft gel capsule to tablet are also presented. The exact dates of each visit depended on the physician's judgment, so data are reported for Visits 1 through 4 rather than by month. Note: participants may have had multiple missed doses or therapy changes.
  • Adverse Events Observed and Development of Lipodystrophy Lesion and Their Locations [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: Yes ]
    The types of adverse events reported are summarized. The presence of lipodystrophy (abnormal body fat distribution) and its location was to be recorded. However, due to an oversight, there was not a place to record the location of lipodystrophy on the case report form. Doctors used clinical judgment to rate lipodystrophy in treatment-experienced participants. Study visits were to occur at approximately 3, 6, 12, and 18 months after starting treatment. The exact dates of each visit depended on the physician's judgment, so data are reported for Visits 1 through 4 rather than by month.
  • The Duration on Treatment Until Development of an Adverse Event Leading to Treatment Discontinuation or Until Escape From Treatment [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: Yes ]
    As so few participants withdrew from lopinavir/ritonavir treatment, durations of lopinavir/ritonavir therapy required for 25 percent, 50 percent and 75 percent of participants could not be established. The numbers of participants in each subgroup who discontinued from treatment due to an adverse event are presented.
  • Frequency of missed doses, number of patients who interrupt or discontinue regimen and number of patients who experience changes in dosage or of combination regimen [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: Yes ]
  • Adverse events observed and development of lipodystrophy lesion and their locations [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: Yes ]
  • The duration on treatment until development of an adverse event leading to treatment discontinuation or until escape from treatment [ Time Frame: Month 3, 6, 12, 18 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China: A Multicenter Post-Marketing Observational Study

This post-marketing observational study is conducted for obtaining data on clinical, biological and virological outcomes, compliance and tolerability of using a lopinavir/ritonavir (LPV/r) -containing regimen for the treatment of naïve or experienced patients infected with human immunodeficiency virus type 1 (HIV-1) in China.

Although LPV/r is frequently used world-wide, the evaluation of the outcomes, compliance, and tolerance of anti-HIV strategies in real life is still a major challenge in the management of HIV-infected patients who are on a life-long therapy, especially in China.

This study will help to develop effectiveness and safety profile of the lopinavir/ritonavir containing regimen in Chinese HIV-1 infected patients, provide more choices of anti-HIV-1 strategies to Chinese experts and benefits Chinese HIV-1 infected patients.

It is planned to enroll approximately 100 patients in total. This will be a multicenter post-marketing observational study in China mainland.

Each patient will be observed during his/her lopinavir/ritonavir - containing treatment regimen for a maximum period of 18 months.

If the physician decides to permanently discontinue lopinavir/ritonavir before the end of the planned observational period of 18 months, the reason for the discontinuation and the new treatment regimen prescribed will be documented. The next routine follow-up visit will be the termination visit for this patient in this study.

This post-marketing observational study will be conducted in a prospective, single-arm, multicenter format.

As this study is observational in nature, its follow-up is not interventional and is left to the judgment of each physician within the 18-month period, which defines the survey for each patient. For indicative purpose, follow-up of patients should enable approximately 4 patient visits during this period. These visits will take place at average intervals of 6 months, apart from the first visit following inclusion (usually at the end of the first 3 treatment months) and apart from visits required because of an intercurrent event. If treatment with lopinavir/ritonavir is discontinued, standard practice is to review the patient after a period of 3 months.

For these reasons, the most likely visits are defined as "V1", "V2", "V3", "V4" although numbers and dates will depend only on the decision of the physician. As a result, failure to meet these suggested dates will not constitute a deviation of the protocol.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Hospital

HIV-1 Infections
Drug: Lopinavir/ritonavir (Kaletra)

Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.

The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study.

Other Names:
  • lopinavir/ritonavir
  • Kaletra
Lopinavir/ritonavir group
This study is a non-interventional, observational study in which lopinavir/ritonavir is prescribed in the usual manner in accordance with the terms of China market authorization with regards to dose, population and indication. It is planned to enroll approximately 100 patients in total.
Intervention: Drug: Lopinavir/ritonavir (Kaletra)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
98
June 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients infected by HIV-1 who are over 18 years old
  • Patients who belong to one of the following cohorts:

    • Antiretroviral naïve patients
    • Antiretroviral experienced patients, irrespective to their immune and viral status and current antiretroviral therapy

Exclusion Criteria:

  • Patients who have been treated with lopinavir/ritonavir
  • Patients who are being treated or will be treated with drugs at risk of interactions with lopinavir/ritonavir
  • Patients who are not tolerant to lopinavir/ritonavir
  • Patients who have uncontrolled AIDS defining disease
  • Patients participating in another clinical trial
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT01074931
P10-398
No
Yue Kang, Abbott China
Abbott
Not Provided
Study Chair: Jian LI, MD Abbott (China)
Abbott
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP